Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant ...

Strong efficacy signals showing 33% ORR, 16.6-month PFS, and 27-month OS, improving on the SOC by 2-3X in a difficult-to-treat populationCompany ...
Stocktwits on MSN

ONCY stock rallies on second fast track designation for experimental cancer drug

The company said that the designation is supported by clinical data which demonstrates a 33% objective response rate for pelareorep-based therapy. ・According to Oncolytics, there are an estimated 2 ...